Will voice-enabled AI have a role in oncology?
Progress in artificial intelligence tools is opening-up novel modalities to provide education and doctor-patient communication
Study findings support a growing shift towards “personalised de-escalation” treatment strategies in anal and rectal cancer care
Reduced-dose chemoradiotherapy and non-surgical strategies show promising outcomes with fewer long-term side-effects in lower gastrointestinal cancers
Tucatinib combo continues to show durable benefit in HER2-mutated metastatic breast cancer
Final data from the SGNTUC-019 trial support the use of the agent with trastuzumab in heavily pretreated patients
Neoadjuvant PD-1 blockade achieves encouraging clinical response in early-stage dMMR tumours
Findings from a small study support a non-surgical and tumour-agnostic approach with immunotherapy, but further research is needed
Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer
Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
TILs show value in predicting relapse risk in TNBC
Retrospective data suggest that patients with low baseline TILs and nodal involvement have poor prognosis despite achieving pathological complete response
Tailored use of chemotherapy may benefit some early-stage ER+/HER2– breast cancers
Results from two studies suggest that withholding chemotherapy for some patients may not impact efficacy, but an understanding of clinical and biological features is paramount
Adding adjuvant pertuzumab demonstrates prolonged survival benefit after 10+ years in HER2+ breast cancer
Final long-term overall survival data from APHINITY confirm the efficacy of dual HER2 blockade in patients with node-positive disease
Study findings refine the use of ctDNA to track resistance to endocrine therapy in advanced breast cancer
A timing window for testing ESR1 mutations in the blood was identified
Will AI reshape breast cancer screening?
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in screening programmes